There are currently 486 clinical trials in Little Rock, Arkansas looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Arkansas for Medical Sciences, Arkansas Children's Hospital, GSK Investigational Site and Arkansas Cancer Research Center at University of Arkansas for Medical Sciences. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults
NCT04262206
Recruiting
PREVENTABLE is a multi-center, randomized, parallel group, placebo-controlled superiority study. Participants will be randomized 1:1 to atorvastatin 40 mg or placebo. This large study conducted in community-dwelling older adults without cardiovascular disease (CVD) or dementia will demonstrate the benefit of statins for reducing the primary composite of death, dementia, and persistent disability and secondary composites including mild cognitive impairment (MCI) and cardiovascular events.
Gender:
All
Ages:
75 years and above
Trial Updated:
06/14/2024
Locations: Little Rock VA Medical Center, Little Rock, Arkansas +1 locations
Conditions: Cognitive Impairment, Mild, Dementia, Cardiovascular Diseases
Register for Updates
Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial
NCT05411081
Recruiting
This phase II trial compares the effect of atezolizumab in combination with usual treatment with cabozantinib to cabozantinib alone in patients with papillary renal cell carcinoma that has spread to other places in the body (metastatic). Papillary renal cell carcinoma (PRCC) is a type of kidney cancer that forms in the lining of the tiny tubes in the kidney that return filtered substances that the body needs back to the blood and remove extra fluid and waste as urine. Most papillary tumors look... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/13/2024
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas
Conditions: Metastatic Papillary Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
Register for Updates
A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder
NCT06021522
Recruiting
The primary objective of this study is to evaluate the long-term safety and tolerability of ecopipam tablets in children (greater than or equal to [>=] 6 and less than [<] 12 years of age), adolescents (>=12 and <18 years of age), and adults (>=18 years of age) with Tourette's Syndrome (TS).
Gender:
All
Ages:
6 years and above
Trial Updated:
06/13/2024
Locations: Arkansas Children's Hospital, Little Rock, Arkansas
Conditions: Tourette Syndrome
Register for Updates
Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria
NCT05936567
Recruiting
This study is being conducted to evaluate the efficacy and safety of povorcitinib in adults with CSU that is inadequately controlled using SOC treatments.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
06/13/2024
Locations: Little Rock Allergy Asthma, Pa Clinical Research Center Lraac, Little Rock, Arkansas
Conditions: Urticaria, Chronic Spontaneous Urticaria, Chronic Idiopathic Urticaria, Hives, Angioedema, Pruritis
Register for Updates
Visualization of the STN and GPi for DBS
NCT05774041
Recruiting
The purpose of the study is to determine if using SIS System for DBS planning results in less distance between the planned target location and the actual implanted lead location than DBS planning without SIS System.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/13/2024
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas
Conditions: Deep Brain Stimulation, Parkinson Disease
Register for Updates
Study to Evaluate the Effects of Oral NMRA 335140 Versus Placebo in Participants With Major Depressive Disorder
NCT06029426
Recruiting
This is a randomized, double blind, placebo controlled, multi-center study to evaluate the effects of NMRA 335140 (formerly BTRX 335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 28 days), and a 6-week Treatment Period (during which participants will receive either NMRA 335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
06/13/2024
Locations: Neumora Investigator Site, Little Rock, Arkansas
Conditions: Major Depressive Disorder
Register for Updates
Study to Assess the Safety and Effectiveness of NMRA-335140-501
NCT06029439
Recruiting
This is a 52-week open-label extension (OLE) study that will evaluate the safety, tolerability, and effectiveness of NMRA-335140 in participants with major depressive disorder (MDD). Participants who completed a parent study investigating the efficacy of NMRA-335140 as a treatment for MDD (ie, NMRA-335140-301, NMRA-335140-302, or NMRA-335140-303), who provide informed consent, and who have no evidence of safety concerns that would preclude treatment with NMRA-335140 may be enrolled into this ext... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
06/13/2024
Locations: Neumora Investigator site, Little Rock, Arkansas
Conditions: Major Depressive Disorder
Register for Updates
Product Surveillance Registry
NCT01524276
Recruiting
The purpose of the Registry is to provide continuing evaluation and periodic reporting of safety and effectiveness of Medtronic market-released products. The Registry data is intended to benefit and support interests of patients, hospitals, clinicians, regulatory bodies, payers, and industry by streamlining the clinical surveillance process and facilitating leading edge performance assessment via the least burdensome approach.
Gender:
All
Ages:
All
Trial Updated:
06/13/2024
Locations: Not set, Little Rock, Arkansas
Conditions: Cardiac Rhythm Disorders, Urological Disorders, Neurological Disorders, Cardiovascular Disorders, Digestive Disorders, Intracranial Aneurysm, Mechanical Circulatory Support, Respiratory Therapy, Aortic, Peripheral Vascular and Venous Disorders, Minimally Invasive Surgical Procedures, Diagnostic Techniques and Procedures, Surgical Procedures, Operative, Renal Insufficiency, Neurovascular, Coronary Artery Disease, Ear, Nose and Throat Disorder
Register for Updates
A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's Disease
NCT06055985
Recruiting
The primary purpose of this study is to demonstrate the superiority of UCB0022 as an adjunctive treatment to stable dose of standard-of-care (SoC) (including at least levodopa therapy) over placebo with regard to motor fluctuations time spent in the OFF state (OFF time) in study participants with advanced Parkinson's Disease (PD).
Gender:
All
Ages:
Between 35 years and 80 years
Trial Updated:
06/13/2024
Locations: Pd0060 50608, Little Rock, Arkansas
Conditions: Parkinson Disease
Register for Updates
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
NCT03488693
Recruiting
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
Gender:
Female
Ages:
35 years and above
Trial Updated:
06/13/2024
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas
Conditions: Breast Cancer
Register for Updates
Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)
NCT04609878
Recruiting
This is a variable length study to evaluate the efficacy and safety of budesonide/glycopyrronium/formoterol inhaler in adults and adolescents with severe asthma inadequately controlled with standard of care
Gender:
All
Ages:
Between 12 years and 80 years
Trial Updated:
06/13/2024
Locations: Research Site, Little Rock, Arkansas
Conditions: Asthma
Register for Updates
Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age
NCT05741476
Recruiting
The primary purpose of this study is to assess the efficacy and safety of daily DBV712 250 micrograms (mcg) to induce desensitization to peanut in peanut-allergic children 4-7 years of age over a 12-month double-blind, placebo-controlled (DBPC) Treatment Period.
Gender:
All
Ages:
Between 4 years and 7 years
Trial Updated:
06/12/2024
Locations: DBV Investigative Site, Little Rock, Arkansas
Conditions: Allergy, Peanut
Register for Updates